Rare Case Report: Therapy-Related Acute Promyelocytic Leukemia (t-APL) in a Young Non-HBV Female After TACE Plus Sintilimab-Lenvatinib for HCC — A Clinical Alert and Literature Review
4 affiliations
- 1Department of Oncology, Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, 646000, People’s Republic of China
- 2Department of Oncology, The First People’s Hospital of Liangshan Yi Autonomous Prefecture, Liangshan, Sichuan, 615000, People’s Republic of China
- 3Nuclear Medicine and Molecular Imaging Key Laboratory of Sichuan Province, Luzhou, Sichuan, 646000, People’s Republic of China
- 4Academician (Expert) Workstation of Sichuan Province, Luzhou, Sichuan, 646000, People’s Republic of China
Abstract
Background: Transarterial chemoembolization (TACE) combined with PD-1 immune checkpoint inhibitor plus lenvatinib is a standard first-line therapy for unresectable hepatocellular carcinoma (HCC). Therapy-related acute promyelocytic leukemia (t-APL) is a rare but life-threatening secondary hematologic malignancy. Reports of t-APL following this triple regimen in non-HBV young female HCC patients remain extremely limited.
Methods: We report a 30-year-old non-HBV female patient with moderately-differentiated HCC diagnosed incidentally in early pregnancy, who received pregnancy termination followed by oxaliplatin-fluorouracil-based TACE, then sintilimab plus lenvatinib maintenance. Clinical, laboratory, bone marrow, imaging and histopathological data were collected. We further performed a systematic review of published t-APL cases in HCC patients treated with targeted-immune therapy up to May 2026.
Results: Approximately 12 months after treatment initiation, the patient developed oral mucosal ecchymosis, fatigue and anorexia. Serial blood tests demonstrated progressive thrombocytopenia and increasing circulating promyelocytes. Bone-marrow examination and FISH confirmed PML/RARA-positive t-APL. Due to economic burden, the patient refused standard all-trans retinoic acid (ATRA) plus arsenic trioxide and died 3 months after t-APL diagnosis. Combined with 11 previously reported cases (total n=12 globally), the median latency from targeted-immunotherapy commencement to t-APL onset was 11 months (range 6–18 months). Pathogenesis may involve synergistic genotoxic injury from TACE chemotherapy, PD-1-mediated immune dysregulation, lenvatinib-associated myelotoxicity and host individual susceptibility.
Conclusion: t-APL is a rare fatal complication of TACE plus sintilimab-lenvatinib for HCC, mostly occurring within 1 year of therapy initiation. Mandatory monthly hematologic monitoring is required during this high-risk window. Prompt bone-marrow evaluation and PML/RARA fusion testing should be performed for unexplained cytopenia or circulating immature myeloid cells to enable timely ATRA-arsenic-based intervention.
Related
- Extramedullary Relapse of Acute Promyelocytic Leukemia in the Middle Ear after All-Trans Retinoic Acid Combined with Chemotherapy
- Severe Multiorgan Failure Associated with Differentiation Syndrome in a High-risk Acute Promyelocytic Leukemia Patient with Concurrent Influenza A
- Acute Promyelocytic Leukemia with t(11;17)(q23.2;q21.2) Treated with Haploidentical Transplantation Using Post-transplant Cyclophosphamide
- PXL: a nucleic acid-binding module of the promyelocytic leukemia protein.
- Secondary Intracranial Hypertension During ATRA/ATO Therapy in High-Risk Acute Promyelocytic Leukemia: A Case Report and Practical Management Framework.
BibTeX
@article{yu2026rare,
title = {{Rare Case Report: Therapy-Related Acute Promyelocytic Leukemia (t-APL) in a Young Non-HBV Female After TACE Plus Sintilimab-Lenvatinib for HCC — A Clinical Alert and Literature Review}},
author = {Rong Yu and Xulin Shi and Huaxi Fan and Guishu Wu and Jing Zhang and Xiangyu Deng and Xiaolong Liu and Mingyue Rao and Jianwen Zhang},
journal = {Journal of Hepatocellular Carcinoma},
year = {2026},
month = oct,
doi = {10.2147/jhc.s656165},
url = {https://doi.org/10.2147/jhc.s656165},
note = {CC BY-NC 4.0},
}
RIS
TY - JOUR
TI - Rare Case Report: Therapy-Related Acute Promyelocytic Leukemia (t-APL) in a Young Non-HBV Female After TACE Plus Sintilimab-Lenvatinib for HCC — A Clinical Alert and Literature Review
AU - Rong Yu
AU - Xulin Shi
AU - Huaxi Fan
AU - Guishu Wu
AU - Jing Zhang
AU - Xiangyu Deng
AU - Xiaolong Liu
AU - Mingyue Rao
AU - Jianwen Zhang
PY - 2026
DA - 2026/10/30
JO - Journal of Hepatocellular Carcinoma
DO - 10.2147/jhc.s656165
UR - https://doi.org/10.2147/jhc.s656165
AB - Background: Transarterial chemoembolization (TACE) combined with PD-1 immune checkpoint inhibitor plus lenvatinib is a standard first-line therapy for unresectable hepatocellular carcinoma (HCC). Therapy-related acute promyelocytic leukemia (t-APL) is a rare but life-threatening secondary hematologic malignancy. Reports of t-APL following this triple regimen in non-HBV young female HCC patients remain extremely limited. Methods: We report a 30-year-old non-HBV female patient with moderately-differentiated HCC diagnosed incidentally in early pregnancy, who received pregnancy termination followed by oxaliplatin-fluorouracil-based TACE, then sintilimab plus lenvatinib maintenance. Clinical, laboratory, bone marrow, imaging and histopathological data were collected. We further performed a systematic review of published t-APL cases in HCC patients treated with targeted-immune therapy up to May 2026. Results: Approximately 12 months after treatment initiation, the patient developed oral mucosal ecchymosis, fatigue and anorexia. Serial blood tests demonstrated progressive thrombocytopenia and increasing circulating promyelocytes. Bone-marrow examination and FISH confirmed PML/RARA-positive t-APL. Due to economic burden, the patient refused standard all-trans retinoic acid (ATRA) plus arsenic trioxide and died 3 months after t-APL diagnosis. Combined with 11 previously reported cases (total n=12 globally), the median latency from targeted-immunotherapy commencement to t-APL onset was 11 months (range 6–18 months). Pathogenesis may involve synergistic genotoxic injury from TACE chemotherapy, PD-1-mediated immune dysregulation, lenvatinib-associated myelotoxicity and host individual susceptibility. Conclusion: t-APL is a rare fatal complication of TACE plus sintilimab-lenvatinib for HCC, mostly occurring within 1 year of therapy initiation. Mandatory monthly hematologic monitoring is required during this high-risk window. Prompt bone-marrow evaluation and PML/RARA fusion testing should be performed for unexplained cytopenia or circulating immature myeloid cells to enable timely ATRA-arsenic-based intervention.
SN - 2253-5969
ER -